Analysis reveals glaucoma therapy persistence varies by drug class and dose, suggesting improvements in drug development and patient counseling.
This study provides the first comprehensive analysis of product-specific persistence rates for topical glaucoma therapies in Japan. Product choice was shown to significantly influence persistence, alongside known factors such as patient sex, age, drug class, and dose/day. These findings have implications for drug development, product selection, and patient counseling aimed at improving the effectiveness and efficiency of long-term glaucoma management.
No takes yet. Share an insight, caveat, or question.
Kabeya et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: